Mishra Ramesh C, Mitchell Jamie R, Gibbons-Kroeker Carol, Wulff Heike, Belenkie Israel, Tyberg John V, Braun Andrew P
Dept. of Physiology & Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; The Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada.
Dept of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Vascul Pharmacol. 2016 Apr;79:24-31. doi: 10.1016/j.vph.2015.07.016. Epub 2015 Aug 1.
SKA-31, an activator of endothelial KCa2.3 and KCa3.1 channels, reduces systemic blood pressure in mice and dogs, however, its effects in larger mammals are not well known. We therefore examined the hemodynamic effects of SKA-31, along with sodium nitroprusside (SNP), in anesthetized, juvenile male domestic pigs. Experimentally, continuous measurements of left ventricular (LV), aortic and inferior vena cava (IVC) pressures, along with flows in the ascending aorta, carotid artery, left anterior descending coronary artery and renal artery, were performed during acute administration of SKA-31 (0.1, 0.3, 1.0, 3.0 and 5.0mg/ml/kg) and a single dose of SNP (5.0 μg/ml/kg). SKA-31 dose-dependently reduced mean aortic pressure (mPAO), with the highest dose decreasing mPAO to a similar extent as SNP (-23 ± 3 and -28 ± 4 mmHg, respectively). IVC pressure did not change. Systemic conductance and conductance in coronary and carotid arteries increased in response to SKA-31 and SNP, but renal artery conductance was unaffected. There was no change in either LV stroke volume (SV) or heart rate (versus the preceding control) for any infusion. With no change in SV, drug-evoked decreases in LV stroke work (SW) were attributed to reductions in mPAO (SW vs. mPAO, r(2)=0.82, P<0.001). In summary, SKA-31 dose-dependently reduced mPAO by increasing systemic and arterial conductances. Primary reductions in mPAO by SKA-31 largely account for associated decreases in SW, implying that SKA-31 does not directly impair cardiac contractility.
SKA - 31是一种内皮钙激活钾通道KCa2.3和KCa3.1的激活剂,可降低小鼠和犬的全身血压,然而,其在较大哺乳动物中的作用尚不清楚。因此,我们研究了SKA - 31与硝普钠(SNP)在麻醉的幼年雄性家猪中的血流动力学效应。实验中,在急性给予SKA - 31(0.1、0.3、1.0、3.0和5.0mg/ml/kg)和单剂量SNP(5.0μg/ml/kg)期间,连续测量左心室(LV)、主动脉和下腔静脉(IVC)压力,以及升主动脉、颈动脉、左前降支冠状动脉和肾动脉中的血流。SKA - 31剂量依赖性地降低平均主动脉压(mPAO),最高剂量降低mPAO的程度与SNP相似(分别为-23±3和-28±4mmHg)。IVC压力未改变。SKA - 31和SNP使全身电导以及冠状动脉和颈动脉的电导增加,但肾动脉电导未受影响。任何输注情况下,LV每搏输出量(SV)或心率(相对于先前对照)均无变化。由于SV无变化,药物引起的LV每搏功(SW)降低归因于mPAO的降低(SW与mPAO,r(2)=0.82,P<0.001)。总之,SKA - 31通过增加全身和动脉电导来剂量依赖性地降低mPAO。SKA - 31对mPAO的原发性降低在很大程度上解释了SW的相关降低,这意味着SKA - 31不会直接损害心脏收缩力。